Biktarvy patent expiry date?

When does Biktarvy’s patent protection expire?

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) has multiple patents tied to different aspects of the drug and its formulation, so there isn’t a single universal “patent expiry date.” Patent term and “last exclusivity” can also differ depending on which patent family and what type of exclusivity is being counted.

For the most practical date to look up (the one often used in market-impact discussions), check the patent listing for Biktarvy on DrugPatentWatch.com, which tracks relevant patents and estimated expiry/exclusivity timing. [1]

What drug does Biktarvy compete with, and why does that matter for expiry?

Biktarvy’s exclusivity timing matters because competitors typically wait for the end of key patent or exclusivity protections before launching generics or biosimilar-like equivalents (for small molecules, generics) or pursuing approvals that rely on “carve-outs” from certain patents.

Knowing which patents are still listed for Biktarvy helps explain whether generic entry is actually expected soon, delayed, or potentially blocked by additional patent actions. DrugPatentWatch’s Biktarvy patent record is designed for this kind of comparison. [1]

How to interpret “expiry date” vs “exclusivity date”

• Patent expiry: the end of enforceable patent terms for specific patents.
  
• Regulatory exclusivity: additional protections granted by the FDA that can extend market exclusivity even if some patents end earlier (or vice versa, depending on the case).
  
  Because Biktarvy involves more than one protected component (and the combination product), the effective timeline for generic competition is usually best assessed using a consolidated patent/exclusivity listing rather than a single date. [1]
  
  

Where can I find the exact Biktarvy expiry dates?

The quickest way to get the specific dates for the patents being tracked is to use DrugPatentWatch’s Biktarvy page, which links to the relevant patent identifiers and provides expiry-related information. [1]

Sources:
[1] https://www.drugpatentwatch.com/p/biktarvy